Apr 2024 $240 M No. 6 $50 to $250 million 7
K2 Therapeutics, Inc.: Raise no. 6, Apr 2024 × Investors in this round 7 investors had bought by the notice of May 6, 2024: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $240 M of $240 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Stein, Ph.D. · Executive Officer, Director Leslie R. Tari, Ph.D. · Executive Officer Preetam R. Shah, Ph.D. · Executive Officer Shane R. Ward · Executive Officer Taylor R. Sandison, M.D. · Executive Officer Bonnie R. Bassler, Ph.D. · Director Carin R. Canale-Theakston · Director Daniel D. Burgess · Director James R. Merson, Ph.D. · Director Laura R. Tadvalkar, Ph.D. · Director Ryan R. Spencer · Director Theodore R. Schroeder · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Shane Ward, Chief Operating Officer, Chief Legal Officer and Secretary. Source: SEC Form D, newest notice filed May 6, 2024. Read the notice at the SEC .
equity SEC Sep 2019 $9 M No. 5 $2 to $10 million 1
K2 Therapeutics, Inc.: Raise no. 5, Sep 2019 × Investors in this round 1 investor had bought by the notice of Sep 13, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice James R Levine · Executive Officer Jeffrey Stein · Executive Officer, Director Jessica R Oien · Executive Officer Neil R Abdollahian · Executive Officer Paul R Daruwala · Executive Officer Taylor R Sandison · Executive Officer Chrysa R Mineo · Director Daniel D Burgess · Director David R Gollaher · Director Theodore R Schroeder · Director Timothy R Franson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jessica Oien, General Counsel & Secretary. Source: SEC Form D, newest notice filed Sep 13, 2019. Read the notice at the SEC .
equity SEC May 2018 $2 M No. 4 Under $2 million 16
K2 Therapeutics, Inc.: Raise no. 4, May 2018 × Investors in this round 16 investors had bought by the notice of May 30, 2018: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $1,950,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Stein · Executive Officer, Director Matthew R Onaitis · Executive Officer Taylor R Sandison · Executive Officer Chrysa R Mineo · Director Daniel D Burgess · Director Robert J Perez · Director Scott M Rocklage · Director Theodore R Schroeder · Director Timothy R Franson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Sales Commission amount also covered the $120.0 million concurrent registered direct offering. The Issuer has also agreed to reimburse the placement agents for certain of their expenses related to the offering in an amount up to $40,000.”On the amounts: “Represents warrants to purchase shares of Common Stock; such warrants have not yet been exercised.”Signed by Matthew Onaitis, Chief Financial Officer. Source: SEC Form D, newest notice filed May 30, 2018. Read the notice at the SEC .
options SEC Oct 2017 $20 M No. 3 $10 to $50 million 16
K2 Therapeutics, Inc.: Raise no. 3, Oct 2017 × Investors in this round 16 investors had bought by the notice of Oct 31, 2017: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $1,098,482
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Stein · Executive Officer, Director Ken R Bartizal · Executive Officer Kevin Forrest · Executive Officer Matthew R Onaitis · Executive Officer Neil R Abdollahian · Executive Officer Paul R Daruwala · Executive Officer Taylor R Sandison · Executive Officer Daniel D Burgess · Director Robert J Perez · Director Scott M Rocklage · Director Theodore R Schroeder · Director Timothy R Franson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Matthew Onaitis, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 31, 2017. Read the notice at the SEC .
equity SEC Feb 2015 $42 M No. 2 $10 to $50 million 19
K2 Therapeutics, Inc.: Raise no. 2, Feb 2015 × Investors in this round 19 investors had bought by the notice of Feb 17, 2015: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $42 M of $42 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dirk Thye · Executive Officer Jeffrey Stein · Executive Officer, Director Ken Bartizal · Executive Officer Kevin Forrest · Executive Officer Paul Daruwala · Executive Officer Dan Burgess · Director Kevin Judice · Director Nina Kjellson · Director Patrick Heron · Director Scott Rocklage · Director Steve Elms · Director Ted Schroeder · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jeffrey Stein, President. Source: SEC Form D, newest notice filed Feb 17, 2015. Read the notice at the SEC .
equity SEC May 2014 $6 M No. 1 $2 to $10 million 1
K2 Therapeutics, Inc.: Raise no. 1, May 2014 × Investors in this round 1 investor had bought by the notice of Jun 17, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Stein · Executive Officer, Director Kevin Forrest · Executive Officer Kevin Judice · Executive Officer, Director Dan Burgess · Director Nina Kjellson · Director Patrick Heron · Director Scott Rocklage · Director Steve Elms · Director Ted Schroeder · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents the value of assets acquired”On a merger: “acquisition of certain assets of another corporation”Signed by Kevin Forrest, Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Jun 17, 2014. Read the notice at the SEC .
equity SEC